Phase 2 trial reports MRD-negative responses with cilta-cel in high-risk smoldering multiple myeloma
A phase 2 trial in high-risk smoldering multiple myeloma found all 20 patients treated with cilta-cel became MRD-negative within two months and remained so after 15.3 months. No disease progression, death, dose-limiting toxicities, or high-grade side effects were observed.